SCHEMBL1829290

SCHEMBL1829290

CCCOc1nc(CBr)nc2oc(-c3cccc(F)c3)nc12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.40
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
UTRN P46939 2/20 0.37
TDP1 Q9NUW8 1/20 0.35
HPN P05981 1/20 0.34
PPARG P37231 3/20 0.33
PPARA Q07869 3/20 0.33
NOTUM Q6P988 2/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
LCLAT1 Q6UWP7 1/20 0.33
TP53 P04637 2/20 0.32
VSIR Q9H7M9 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1830149 0.84 MAOB (0.39) MAOBMEN1MAPTKMT2AUTRN
SCHEMBL1828663 0.83 MAOB (0.37) MAOBMEN1MAPTKMT2AUTRN
SCHEMBL1829200 0.83 PDE4B (0.42) MAOBMEN1MAPTKMT2ATDP1
SCHEMBL1828867 0.78 ALDH1A1 (0.46) MAPTLCLAT1TP53SMN1; SMN2
SCHEMBL1828743 0.77 MAPT (0.33) MEN1MAPTKMT2APPARGTP53
SCHEMBL1828263 0.73 RAB9A (0.39) MEN1MAPTKMT2APPARGPPARA
SCHEMBL1828532 0.72 MAPT (0.38) MEN1MAPTKMT2ATDP1NOTUM
SCHEMBL1830757 0.71 PBRM1 (0.36) MEN1MAPTKMT2ATDP1PPARG
SCHEMBL1831078 0.71 ALDH1A1 (0.39) MAPTTDP1
SCHEMBL2146207 0.71 S1PR1 (0.39) MEN1MAPTKMT2ATDP1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735387-B2 Oxazolopyrimidines as Edg-1 receptor agonists SANOFI (FR) 2014-05-27 US disclosed
EP-2583720-A1 Oxazolopyrimidines as Edg-1 receptor agonists SANOFI (FR) 2013-04-24 EP disclosed
EP-2318415-B1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS SANOFI SA (FR) 2013-02-20 EP disclosed
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS SANOFI-AVENTIS (FR) 2011-08-04 US disclosed
EP-2318415-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS Sanofi-Aventis (FR) 2011-05-11 EP disclosed
WO-2010006704-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS SANOFI-AVENTIS (FR) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS EDNRA, OXGR1, EDF1 MAOB 1195/4885MEN1 4180/4885MAPT 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.